Insulet Corporation $PODD Shares Sold by One Way Holdings LLC

One Way Holdings LLC lessened its holdings in Insulet Corporation (NASDAQ:PODD) by 91.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,784 shares of the medical instruments supplier’s stock after selling 48,334 shares during the period. One Way Holdings LLC’s holdings in Insulet were worth $624,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Insulet in the third quarter worth approximately $2,758,000. ProShare Advisors LLC grew its position in Insulet by 6.0% during the third quarter. ProShare Advisors LLC now owns 20,802 shares of the medical instruments supplier’s stock valued at $2,714,000 after buying an additional 1,185 shares during the period. Vise Technologies Inc. increased its holdings in Insulet by 52.9% during the third quarter. Vise Technologies Inc. now owns 5,503 shares of the medical instruments supplier’s stock valued at $718,000 after buying an additional 1,903 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Insulet by 61,543.8% during the third quarter. International Assets Investment Management LLC now owns 45,000 shares of the medical instruments supplier’s stock valued at $5,871,000 after buying an additional 44,927 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Insulet by 144.7% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,356 shares of the medical instruments supplier’s stock valued at $3,308,000 after buying an additional 14,996 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Sanford C. Bernstein decreased their price target on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Leerink Partners downgraded shares of Insulet from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $247.00 to $145.00 in a research report on Thursday, August 6th. Truist Financial lowered Insulet from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $210.00 to $153.00 in a research note on Wednesday, August 5th. Robert W. Baird set a $175.00 price objective on Insulet in a research note on Thursday, August 6th. Finally, BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $186.68.

Insulet Trading Up 2.6%

Insulet stock opened at $153.61 on Tuesday. The firm has a 50 day moving average of $141.02 and a 200 day moving average of $179.25. The firm has a market capitalization of $10.65 billion, a price-to-earnings ratio of 28.71, a P/E/G ratio of 1.17 and a beta of 1.11. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter last year, the business earned $1.17 EPS. The firm’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.